In This issue

Krivoy and colleagues (pages 226-231) examined serum neurotrophins and glutamate levels as putative biomarkers for clozapine response in 89 chronic schizophrenia patients on clozapine (54 responders and 35 non-responders). Responders had higher mean BDNF l and higher serum glutamate levels. These findings suggest that serum glutamate and BDNF can discriminate between clozapine responders and non-responders. However, the question whether peripheral levels of BDNF and glutamate reflect their brain concentrations is unclear.
Source: Schizophrenia Research - Category: Psychiatry Tags: Invited commentary Source Type: research